Bogart Wealth LLC Has $4.43 Million Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Bogart Wealth LLC boosted its stake in Edwards Lifesciences Co. (NYSE:EW) by 8.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 67,111 shares of the medical research company’s stock after acquiring an additional 5,408 shares during the period. Bogart Wealth LLC’s holdings in Edwards Lifesciences were worth $4,429,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Crewe Advisors LLC bought a new position in shares of Edwards Lifesciences during the 1st quarter worth approximately $28,000. First Community Trust NA acquired a new stake in Edwards Lifesciences in the second quarter worth $29,000. Riverview Trust Co bought a new stake in Edwards Lifesciences in the first quarter valued at $34,000. Webster Bank N. A. acquired a new position in shares of Edwards Lifesciences during the second quarter valued at about $39,000. Finally, Peoples Bank KS bought a new position in shares of Edwards Lifesciences during the 3rd quarter worth about $40,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Ratings Changes

EW has been the subject of a number of research reports. Canaccord Genuity Group reduced their price objective on Edwards Lifesciences from $77.00 to $66.00 and set a “hold” rating for the company in a research note on Monday, October 7th. Stifel Nicolaus decreased their price target on shares of Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating for the company in a research note on Thursday, July 25th. UBS Group dropped their price objective on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating on the stock in a research note on Tuesday, September 10th. Barclays lowered their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a report on Monday, September 9th. Finally, TD Cowen lowered Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $100.00 to $70.00 in a report on Thursday, July 25th. Fifteen investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Edwards Lifesciences has a consensus rating of “Hold” and an average target price of $75.81.

Insider Activity

In related news, VP Daveen Chopra sold 1,250 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the transaction, the vice president now owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total transaction of $333,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,133,916.72. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the transaction, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 16,250 shares of company stock worth $1,099,238 over the last ninety days. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock traded down $0.03 during mid-day trading on Thursday, reaching $70.58. The company’s stock had a trading volume of 2,153,135 shares, compared to its average volume of 4,555,578. The company has a market capitalization of $42.53 billion, a P/E ratio of 30.44, a PEG ratio of 2.83 and a beta of 1.13. The firm’s fifty day moving average price is $68.04 and its two-hundred day moving average price is $78.71. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The company had revenue of $1.63 billion for the quarter, compared to analyst estimates of $1.65 billion. During the same period in the previous year, the company posted $0.66 EPS. The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. Sell-side analysts predict that Edwards Lifesciences Co. will post 2.71 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.